Discover a new way to find and share stories you'll loveā€¦ Learn about Reading Desk

Blog Profile / In the Pipeline

Filed Under:Medical / Pharmaceutical
Posts on Regator:2059
Posts / Week:9.3
Archived Since:November 3, 2010

Blog Post Archive

Sanofi's Search

Have you noticed that Sanofi hasn't named a replacement yet for their ousted CEO Chris Viehbacher? It doesn't seem to be for lack of trying. Stories have come out over the last few months about various people who have been said to have been under consideration, but...nothing. Show More Summary

Underpowered And Overinterpreted

Time for another "watch those statistics" post. I did one about this time last year, and I could do one every couple of months, to be honest. Here's a good open-access paper from the Royal Society on the problem of p-values, and why there are so many lousy studies out there in the literature. Show More Summary

Instant Azides, and More

I like this reaction, highlighted by See Arr Oh here. It comes in and adds an azide group where there used to be just an alkyl CH bond. That's an instant amine group, naturally, via reduction, as well as an instant triazole should you be in to that sort of thing. Show More Summary

Flex Pharmaceuticals Is Testing What?

Flex Pharmaceuticals went public the other day, another in the string of IPOs in the biopharma world. This is also another Christopher Westphal company - he was a founder of Sirtris, about which much ink and many pixels (here and elsewhere) have been shed, and more recently founded Verastem (who also went public with alacrity). Show More Summary

Expensive Placebos Work Better

The placebo effect weirds everyone out. I think we can say that without much fear of contradiction. It seems like magic, the fact that just thinking that you're getting some treatment of benefit can have actual benefits. Magic, though, it is not. Show More Summary

The ACS Becomes Invisible (But Not For Long)

Here's what looks like a weird publishing decision: the American Chemical Society seems to have blocked search engines for its publications. Try it: type "JACS" into Google, and you'll no longer get the journal's page showing up in the search results. Show More Summary

Cuckoo For Publishing Fees

The scam publishers line up, once again, to publish a manuscript full of gibberish. This one is titled "Cuckoo For Cocoa Puffs", and is authors, ostensibly, by Pinkerton LeBrain and Orson Welles. Seventeen "publishers" have acceptedShow More Summary

Refold Those Proteins

Anyone who expresses and purifies proteins for a living has had to do plenty of refolding over the years. Some proteins are rock-solid rock stars - carbonic anhydrase, say. You can do most anything to them and they just shrug it off....Show More Summary

Interview Question Psy-Ops

Chemjobber picks up here on an interesting letter to C&E News. What do you do, on a job interview, when your interviewer says something that's obviously wrong? In my case, however, there was not an explicit question being asked. Rather,...Show More Summary

Inside the Dr. Oz PR Machine

I mentioned last fall that the Federal Trade Commission had gone after an egregiously faked-up "study" that was being used to sell green coffee bean extract as some sort of miracle weight-loss drug on the Dr. Oz show. The agency hasShow More Summary

OK, You San Diego People

I've already been hearing from people out on the West Coast about how it's seventy-odd Fahrenheit out there. My first thought was "It's five AM out in San Diego; why aren't you asleep rather than looking at the thermometer?" But as for the Cambridge/Boston biopharma world, yeah, we're mostly at home today. Show More Summary

India's GVK Accused of Systematic Fraud

This does not look good at all. The European Medicines Agency (EMA) has accused the large Indian generic company (and outsourcing contractor) GVK of widespread systematic fraud. According to this press release, the agency investigated...Show More Summary

Tolerant Chemistry: Be Glad of It

Like a lot of other scientists in the Northeast today, I'm getting things in the lab ready for me not being there tomorrow. (I just ran into a colleague who didn't know that we're set to get two to three feet of snow, distributed by 50 mile-per-hour winds, over the next 36 hours, and he was not happy to get the news from me). Show More Summary

Are New Biopharmas Being Formed Quickly Enough?

So we've been having an extraordinary bull market for new biopharma companies - just look at the number that have gone public the last few months. (The past two years have beaten the numbers put up in the previous ten!) And it's notShow More Summary

GSK Cuts Back in China (?)

Here's a report that GSK is cutting back severely in China - 1,000 workers during the first part of this year. seems to be first out with this story; others are quoting them. They refer to "sources close to the company", apparently employees who have already had word of the cutbacks. Show More Summary

Elizabeth Warren's "Pharma Swear Jar" Idea

Elizabeth Warren has come out with a proposal for what she's calling a "pharmaceutical swear jar". Once a drug company had been fined, this bill would earmark a percentage of their profits over a multiyear period for use in NIH funding. Show More Summary

Get Your Spirocyclic Compounds Here

If you do early-stage medicinal chemistry, you'll probably be interested in this overview of spirocyclic scaffolds. It has examples from the recent literature, and an update on synthetic methods to get into this chemical space. I've made several compounds like this over the years, without much success in the assays so far. Show More Summary

A Look At Actavis

This profile of Actavis CEO Brent Saunders (by Matthew Herper) makes interesting reading, if your definition of "interesting" is roomy enough to take in various shades of "unnerving" and "enraging". They're the company that saved Allergan...Show More Summary

The State of US Medical Research

Here's a look at the state of medical research in the US versus other developed countries (open-access article at JAMA). Some things to note from that chart: (1) research funding has been pretty flat the last few years, with the only exception being the stimulus-package burst of cash. Show More Summary

Maybe Don't Refund That Grant Money After All

Setting what is nearly a new personal record, I'm backtracking on my approval yesterday of the idea of granting agencies getting a refund for retracted papers. The problems I mentioned in that post, along with the arguments of many in...Show More Summary

Copyright © 2011 Regator, LLC